# Secondary Prevention of Venous Thrombo Embolism (VTE).

> **NCT00329238** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2867 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT00329238
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 2867 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329238, "Secondary Prevention of Venous Thrombo Embolism (VTE).". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT00329238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*